Executive Snapshot

• MRK printed a Q4 2025 beat: $16.40B revenue vs $16.19B est (+1.30%) and $2.04 EPS vs $2.01 est (+1.49%).
• The stock’s near-term debate is 2026 profitability, not 2025 execution: FY26 non-GAAP EPS guidance midpoint $5.075 vs street ~$6.20 (–18.15% gap).
• Top-line guidance looks more stable: FY26 revenue midpoint $66.75B vs ~$66.2B (+0.83%).
• Profitability setup: TTM gross margin 77.18% and TTM operating margin 34.86%, but FY26 calls for ~74%–75% non-GAAP gross margin and $23.5B–$24.5B opex.
• Positioning: $115.84 is ~2.2% below the 52-week high ($118.46) and implies less “valuation cushion” if guidance stays conservative.

What’s Moving The Stock Now

Recent headlines centered on a familiar pattern for large-cap pharma: solid quarter-level execution paired with a forward-year outlook that re-anchors expectations.

MRK’s Q4 print cleared consensus on both revenue and EPS, but the market’s attention quickly shifted to FY2026 earnings power, where the company’s non-GAAP EPS range came in materially below what investors were leaning on pre-release. In practice, that kind of reset tends to matter more than a modest quarterly beat because it reframes:

1. how much margin headwind management is implicitly underwriting, and
2. how quickly new growth drivers can offset maturation in legacy pillars.

Expectations Gap

Q4 2025: modest beat, consistent with the 2025 pattern

• Revenue: $16.40B vs $16.19B est → +$0.21B (+1.30%)
• EPS: $2.04 vs $2.01 est → +$0.03 (+1.49%)

FY2026: revenue broadly in line, EPS guidance implies a step-down

• Revenue guidance midpoint: $66.75B vs street ~$66.2B → +0.83%
• Non-GAAP EPS guidance midpoint: $5.075 vs street ~$6.20 → –18.15%

That divergence (revenue modestly ahead while EPS is materially below) typically points to margin/mix and cost headwinds rather than a deterioration in underlying demand.

Operating Read-Through

Mix: pharma dominates, so the “core” matters most

MRK is overwhelmingly a pharma business in this dataset:

• Pharmaceutical: $57.40B (89.5%) of FY2024 revenue
• Animal Health: $5.88B (9.2%), a meaningful stabilizer but not the main earnings driver

Geographically, FY2024 revenue is U.S.-weighted:

• U.S.: $32.28B (~50%), EMEA: $14.04B (~22%), China: $5.49B (~9%)
  This matters because regional pricing, access, and FX can create real quarterly volatility even when global demand is steady.

Margins: strong trailing, but FY26 implies normalization

• FY2024 gross margin: 76.32%; TTM gross margin: 77.18%
• FY2024 operating margin: 31.51%; TTM operating margin: 34.86%

Now compare that with the company’s FY2026 outlook:

• Non-GAAP gross margin ~74%–75% suggests a step-down vs FY2024 levels.
• Non-GAAP opex $23.5B–$24.5B keeps the cost base elevated.

The combination effectively says: MRK can likely hold the top line, but investors should expect less operating leverage than the trailing margin profile might imply.

Cash conversion: still a core strength

• FY2024 free cash flow: $18.10B (FCF margin ~28.2%)
• TTM free cash flow: $13.05B (FCF margin ~20.3%)
• TTM capex: $4.02B, implying operating cash flow of ~$17.07B

That level of cash generation is why MRK can run an aggressive R&D program (FY2024 $17.94B) while maintaining shareholder returns (TTM dividend yield 2.84%) and balance-sheet flexibility.

Valuation + positioning

• P/E 15.3x with 2.84% dividend yield frames MRK as a “cash-generative large-cap pharma” trade rather than a high-multiple growth compounder.
• 52-week range: $73.31–$118.46; current $115.84 sits near the top of the range (closer to high than low).
• Recent performance is strong (3M +37.27%, 6M +45.05%), which can amplify sensitivity to guidance resets - especially when the “miss” is on EPS rather than revenue.

Put differently: with the stock already priced toward the upper end of its range, the setup implies investors may demand clear evidence that FY26 profitability is conservative (or improving) before extending the multiple further.

Catalysts

• Management follow-through on FY26 EPS bridge: clarity on what’s driving the gap (mix, investment, one-offs, cadence).
• Updates on key growth drivers referenced in guidance commentary (launch scaling / pipeline milestones).
• Capital allocation signals: pace of investment vs shareholder returns, given TTM FCF $13.05B and net debt ~$23.21B.

Risks

Earnings power risk: FY26 non-GAAP EPS midpoint is –18.15% vs street, and if fundamentals don’t improve, that gap can act as an overhang.

• Margin compression risk: FY26 ~74%–75% gross margin implies a lower profile vs FY2024/TTM levels, limiting operating leverage.
• Cost discipline risk: $23.5B–$24.5B opex range is large in absolute terms; small changes in execution can swing EPS meaningfully.
• Balance sheet sensitivity: TTM net debt ~$23.21B and interest expense ~$1.27B mean higher-for-longer rates remain a headwind at the margin.
• Concentration risk (structural): with ~89.5% of revenue from pharma, product-cycle transitions matter disproportionately.

Bottom Line

MRK’s Q4 delivered what investors typically want - a clean beat on revenue and EPS - but the stock reaction is better explained by the FY26 earnings reset, where management’s midpoint non-GAAP EPS guide materially undershot pre-release expectations. The current setup implies MRK can still look attractive as a cash-generative compounder (strong margins and FCF), but near-term upside likely depends on whether FY26 guidance proves conservative and whether margin and cost headwinds are more timing-related than structural.

Sources:

• Gurufocus - Merck & Co Inc - https://www.gurufocus.com/stock/MRK/article
• MERCK - Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/

Disclaimer: Musaffa Academy articles are provided for informational purposes only, and are not research reports or legal, tax, investment, or financial advice. Content may include historical or hypothetical data; past performance does not guarantee future results.

Stock screenings, halal status, grades, and classifications are based on AAOIFI methodology and the oversight of Musaffa’s Shariah scholars. The content is not tailored to your financial situation, risk tolerance, or investment objectives. Always conduct your own research or consult a qualified financial advisor before making decisions.

Musaffa Islamic Social Responsible Investing (MISRI) proprietary rankings are internally developed by Musaffa and are currently in beta. While we continuously work to improve accuracy and reliability, no guarantees are made regarding completeness or correctness.

Logos and brand names are used for identification only and do not imply endorsement. Information is accurate as of the publication date and may change. All content, materials, and methodologies are the exclusive property of Musaffa and are protected by copyright law.

For full details, please visit: https://musaffa.com/disclaimer